Comparison · NCT02753530-deaths
Arimoclomol (20 Months) vs Placebo (20 Months): deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arimoclomol (20 Months) vs Placebo (20 Months): deaths from any cause. Trial comparisons, record NCT02753530-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02753530-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0137 | 0.00242 | 0.0736 | wilson | |
| Risk in group 2 | 0.0128 | 0.00227 | 0.0691 | wilson | |
| Risk difference, group 1 minus group 2 | 0.000878 | -0.0565 | 0.0617 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.07 | 0.0681 | 16.8 | log | |
| Odds ratio, group 1 over group 2 | 1.07 | 0.0657 | 17.4 | log | |
| Number needed to harm, for one more death from any cause on Arimoclomol (20 Months) than on Placebo (20 Months) | 1,140 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arimoclomol (20 Months) | Arimoclomol base 248 mg 3 times daily for 20 months | 1 | 73 | EG000 |
| Group 2 | Placebo (20 Months) | Matching placebo 3 times daily for 20 months | 1 | 78 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- From first dose of study medication until 14 days following the latest administration of study medication. Assessed monthly for the first 6 months, and then every second month until Month 20.
Source ClinicalTrials.gov
Trial
- Title
- Study of Arimoclomol in Inclusion Body Myositis (IBM)
- NCT number
- NCT02753530
- Phases
- PHASE2
- Conditions
- Inclusion Body Myositis
- Interventions
- Arimoclomol, Placebo
- Lead sponsor
- ZevraDenmark
- Results first posted
- 2023-05-10
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02753530?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02753530-deaths